Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

Pathobiology

Volumn 79, Issue 2, 2012, Pages 101-106

  Higashi, Michiyo ^a   Yamada, Norishige ^a   Yokoyama, Seiya ^a   Kitamoto, Sho ^a   Tabata, Kazuhiro ^a   Koriyama, Chihaya ^a   Batra, Surinder K ^b   Yonezawa, Suguru ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CA125; Cholangiocarcinoma; MUC16; Prognosis

Indexed keywords

CA 125 ANTIGEN; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M11; MUCIN 1; MUCIN 2; MUCIN 4; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCTS, INTRAHEPATIC; CA-125 ANTIGEN; CHOLANGIOCARCINOMA; FEMALE; GPI-LINKED PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN-1; MUCIN-2; MUCIN-4; PROGNOSIS;

EID: 84856175874     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000335164     Document Type: Article

References (25)

1. Nakanuma Y, Curado MP, Franceschi S, Gores G, Paradis V, Sripa B, Tsui WMS, Wee A: Intrahepatic cholangiocarcinoma; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010, pp 217-219.
2. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999; 30: 1347-1355.
3. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-4262.
4. Kokudo N, Makuuchi M: Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2002; 11: 969-983. (Pubitemid 35397233)
5. Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60. (Pubitemid 38082153)
6. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aikou T, Tanaka S, Irimura T, Kim YS, Sato E: Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998; 4: 2605-2614. (Pubitemid 28523486)
7. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M: Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008; 8: 3329-3341.
8. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, Osako M, Takao S, Batra SK, Aikou T, Imai K, Yonezawa S: MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005; 58: 845-852. (Pubitemid 41113392)
9. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004; 39: 220-229. (Pubitemid 38461485)
10. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 2006; 12: 4257-4264.
11. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001; 22: 348-366. (Pubitemid 34062947)
12. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K: The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002; 23: 154-169. (Pubitemid 44858307)
13. Yin BW, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371-27375.
14. Cioffi M, Fratta M, Gazzerro P, Di Finizio B, Tucci A, Mollinari AM: OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease. Tumori 1997; 83: 594-598. (Pubitemid 27314573)
15. Higashi M, Goto M, Saitou M, Shimizu T, Rousseau K, Batra SK, Yonezawa S: Immunohistochemical study of mucin expression in periampullary adenomyoma. J Hepatobiliary Pancreat Sci 2010; 17: 275-283.
16. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ: Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999; 52: 283-290. (Pubitemid 29161492)
17. McCluggage WG: Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000; 53: 327-334. (Pubitemid 30256898)
18. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766-3772. (Pubitemid 40685594)
19. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M: Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002; 89: 1525-1531. (Pubitemid 35404319)
20. Hardardottir H, Parmley TH 2nd, Quirk JG Jr, Sanders MM, Miller FC, O'Brien TJ: Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 1990; 163: 1925-1931.
21. Kobayashi H, Ohi H, Moniwa N, Shinohara H, Terao T: Characterization of CA 125 antigen identified by monoclonal antibodies that recognize different epitopes. Clin Biochem 1993; 26: 391-397. (Pubitemid 23326742)
22. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS: Mesothelin-MUC16 binding is a high affinity, N-glycan-dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50.
23. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M: A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92: 2374-2383. (Pubitemid 33029082)
24. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S: Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505. (Pubitemid 30257507)
25. Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Tsuneyoshi M: The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol 2002; 15: 1181-1190. (Pubitemid 35435136)